Xeris pharmaceuticals, inc. (XERS)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Dec'17
Assets
Current Assets
Cash and cash equivalents

39,244

19,519

56,160

66,669

61,984

45,716

75,745

134,528

42,045

Short-term Investments

57,698

56,030

46,311

57,841

85,687

66,917

55,296

-

0

Trade accounts receivable, net

2,531

4,693

-

-

-

-

-

-

-

Trade accounts receivable, net

-

-

874

826

3,628

0

1,731

1,065

1,199

Other accounts receivable, net

727

946

-

-

-

2,869

-

-

-

Inventory

2,166

2,176

-

-

-

0

-

-

-

Prepaid expenses and other current assets

3,154

4,119

2,631

813

2,146

2,397

2,898

1,439

809

Total current assets

105,520

87,483

105,976

126,149

153,445

117,899

135,670

137,032

44,053

Investments

2,992

13,231

13,913

-

-

0

-

-

-

Property and equipment, net

7,593

7,853

7,952

7,677

7,430

2,034

1,826

1,136

788

Other assets

357

420

259

68

95

95

95

88

157

Total assets

116,462

108,987

128,100

133,894

160,970

120,028

137,591

138,256

44,998

Liabilities and Stockholders' Equity
Current Liabilities
Accounts payable

3,840

5,603

1,678

1,840

1,408

866

622

556

1,976

Other accrued liabilities

13,824

18,119

15,706

15,609

11,482

8,214

6,260

7,542

2,557

Accrued trade discounts and rebates

1,719

1,375

-

-

-

0

-

-

-

Accrued returns reserve

2,336

1,957

-

-

-

0

-

-

-

Other current liabilities

161

284

-

-

-

1,092

-

-

-

Long-term Debt and Capital Lease Obligations, Current

-

-

-

3,000

-

-

-

-

-

Warrants liabilities

-

-

302

403

295

-

1,042

807

93

Deferred grant awards

-

-

106

156

221

-

284

284

234

Total current liabilities

21,880

27,338

17,792

21,008

13,406

10,172

8,208

9,189

4,860

Long-term debt, net of unamortized deferred costs

58,485

58,305

58,124

29,403

32,141

31,890

31,642

18,167

0

Other liabilities

9,028

8,908

8,528

8,692

8,323

2,560

2,621

1,563

90

Total liabilities

89,393

94,551

84,444

59,103

53,870

44,622

42,471

28,919

4,950

Commitments and Contingencies (Note 8)

-

-

-

-

-

-

0

0

-

Series A Convertible Preferred Stock, par value $0.0001

-

-

-

-

-

-

0

0

1,945

Series B Convertible Preferred Stock, par value $0.0001

-

-

-

-

-

-

0

0

18,536

Series C Convertible Preferred Stock, par value $0.0001

-

-

-

-

-

-

0

0

77,397

Total convertible preferred stock

-

-

-

-

-

-

0

0

97,878

Stockholders' Equity
Preferred Stock, par value $0.0001

0

0

0

0

0

0

0

0

0

Common stock, par value $0.0001

4

3

3

3

3

2

2

2

1

Additional paid in capital

302,434

260,635

256,771

255,047

253,040

196,121

195,422

194,813

2,754

Accumulated deficit

-275,400

-246,245

-213,200

-180,327

-145,900

-120,665

-100,246

-85,478

-60,585

Accumulated other comprehensive income

60

43

45

68

-1

-52

-58

-

0

Total stockholders' equity

27,069

14,436

43,656

74,791

107,100

75,406

95,120

109,337

-57,830

Total liabilities and stockholders' equity

116,462

108,987

128,100

133,894

160,970

120,028

137,591

138,256

44,998

Preferred Stock, Shares Authorized

10,000

10,000

-

-

-

-

-

-

-

Preferred Stock, Par Value Per Share

0.00

0.00

-

-

-

-

-

-

-

Common Shares, Par Value Per Share

0.00

0.00

-

-

-

-

-

-

-

Common Stock, Shares Authorized

150,000

150,000

-

-

-

-

-

-

-

Common Stock, Shares, Issued

37,541

27,214

-

-

-

-

-

-

-